Clinical Trial Update: Felzartamab in Late Antibody-Mediated Rejection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for felzartamab in antibody-mediated rejection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• Felzartamab (felzartamab)

Snippet

Sponsor: Farsad Eskandary | Conditions: Antibody-mediated Rejection | Phase 2 | Status: COMPLETED